Dovitinib

Dovitinib

产品活性：Dovitinib是多靶点的酪氨酸激酶抑制剂，抑制FLT3，c-Kit，FGFR1/3，VEGFR1/2/3 和 PDGFRα/β 的 IC₅₀ 值分别为1，2，8/9，10/13/8，27/210 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：c-Kit  |  FLT3  |  FGFR  |  VEGFR  |  PDGFR

In Vitro: Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC₅₀ values of 25 nM. B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC₅₀ of values of 90 nM (KMS11 and OPM2) and 550 nM, respectively^[1]. Dovitinib significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells^[2]. Dovitinib enhances the BMP-2-induced alkaline phosphatase (ALP) induction, which is a representative marker of osteoblast differentiation. Dovitinib also stimulates the translocation of phosphorylated Smad1/5/8 into the nucleus and phosphorylation of mitogen-activated protein kinases, including ERK1/2 and p38^[3]. Dovitinib strongly inhibits both the interaction of TNIK with ATP (K_i, 13 nM) and the activation of Wnt signaling effectors such as β-catenin and TCF4. Dovitinib also induces caspase-dependent apoptosis in IM-9 cells without significant cytotoxicity in PBMCs^[4].

In Vivo: Dovitinib (10 mg/kg, 30 mg/kg, 60 mg/kg, p.o.) shows significant antitumor effect in the KMS11-bearing mice model, and the growth inhibition is 48%, 78.5%, and 94% in the 10 mg/kg, 30 mg/kg, and 60 mg/kg treatment arms, respectively, compared with the placebo-treated mice^[1]. Dovitinib (50 and 75 mg/kg) results in 97% and 98% tumor growth inhibition, respectively, and the maximal efficacy is at 50 mg/kg^[2].

相关产品：Kinase Inhibitor Library  |  Clinical Compound Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Bioactive Compound Library Plus  |  Sorafenib  |  Pexidartinib  |  Lenvatinib  |  Nintedanib  |  Regorafenib  |  Cabozantinib  |  Ponatinib  |  Infigratinib  |  Sunitinib  |  Semaxinib  |  Imatinib  |  AZD4547  |  Quizartinib  |  Bevacizumab  |  Gilteritinib  |  Apatinib  |  Vandetanib  |  Crenolanib  |  Pazopanib  |  Axitinib  |  Pacritinib  |  PD173074  |  Erdafitinib  |  Foretinib  |  Heparan Sulfate  |  SU 5402  |  Linifanib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。